Floatz logo

1,380 assets in Cancer

Therapeutic assets addressing Cancer, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Celecoxib
Cancer
Emory UniversityP2CCC (48)
Chiauranib
Cancer
Chipscreen Biosciences, Ltd.P1/2CCC (48)
d3s-002
Cancer
D3 Bio (Wuxi) Co., LtdP1/2CCC (48)
Darolutamide
Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsP1/2CCC (48)
Dual-Target Car-Nk Cells
Cancer
Beijing BiotechP1/2CCC (48)
Ecubectedin
Cancer
Grupo Espanol de Investigacion en SarcomasP1/2CCC (48)
Elisrasib
Cancer
D3 Bio (Wuxi) Co., LtdP1/2CCC (48)
Entinostat
Cancer
National Cancer Institute (NCI)P1CCC (48)
es102
Cancer
Elpiscience Biopharma, Ltd.P1CCC (48)
Firi-Cel
Cancer
CARGO TherapeuticsP2CCC (48)
iap0971
Cancer
SUNHO（China）BioPharmaceutical CO., Ltd.P1/2CCC (48)
ibb0979
Cancer
SUNHO（China）BioPharmaceutical CO., Ltd.P1/2CCC (48)
ima402
Cancer
Immatics Biotechnologies GmbHP1/2CCC (48)
Immunotherapic Bifunctional Fusion Protein Comprised Of A Fully Human Igg1 Monoclonal Antibody (Avelumab) Against Human Programmed Death-Ligand 1 (Pd-L1) Fused To The Soluble Extracellular Domain Of Transforming Growth Factor-.Beta. (Tgf-.Beta.) Receptor Ii, Which Acts As A Tgf-.Beta. Trap
Cancer
EMD Serono Research & Development Institute, Inc.P3CCC (48)
Isatuximab
Cancer
UNC Lineberger Comprehensive Cancer CenterP2CCC (48)
Itnk Cell Therapy
Cancer
Second Affiliated Hospital of Guangzhou Medical UniversityP1/2CCC (48)
Ivonescimab
Cancer
Cancer Institute and Hospital, Chinese Academy of Medical SciencesP1/2CCC (48)
Ivosidenib
Cancer
Jason J. Luke, MDP2CCC (48)
Jskn003
Cancer
Jiangsu Alphamab Biopharmaceuticals Co., LtdP1/2CCC (48)
lm-299
Cancer
LaNova Medicines LimitedP1/2CCC (48)
lm-350 for
Cancer
LaNova Medicines LimitedP1/2CCC (48)
Lomustine
Cancer
Actuate Therapeutics Inc.P2CCC (48)
Lopinavir
Cancer
DualityBio Inc.P2CCC (48)
Lorlatinib
Cancer
Strata OncologyP2CCC (48)
Np-G2-044
Cancer
Novita Pharmaceuticals, Inc.P1/2CCC (48)
Panax Ginseng
Cancer
M.D. Anderson Cancer CenterP1/2CCC (48)
Pan-Fgfr Tyrosine Kinase Inhibitor Jnj-42756493
Cancer
Janssen Research & Development, LLCP2CCC (48)
Paxalisib
Cancer
Australian & New Zealand Children's Haematology/Oncology GroupP1/2CCC (48)
Prag-1
Cancer
Second Affiliated Hospital of Soochow UniversityP2CCC (48)
prt3789
Cancer
Prelude TherapeuticsP2CCC (48)
Pyruvate
Cancer
National Heart Centre SingaporeP2CCC (48)
Relebactam
Cancer
M.D. Anderson Cancer CenterP2CCC (48)
Risovalisib
Cancer
Haihe Biopharma Co., Ltd.P2CCC (48)
Selpercatinib
Cancer
Eli Lilly and CompanyP1/2CCC (48)
Shr-1802
Cancer
Shanghai Hengrui Pharmaceutical Co., Ltd.P2CCC (48)
Shr-A1921
Cancer
Shanghai Hengrui Pharmaceutical Co., Ltd.P1/2CCC (48)
Slc-3010
Cancer
Yonsei UniversityP2CCC (48)
Stenoparib
Cancer
Allarity TherapeuticsP1/2CCC (48)
Surufatinib
Cancer
Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyP2CCC (48)
tcc1727
Cancer
Beijing Tide Pharmaceutical Co., LtdP1/2CCC (48)
Tegafur
Cancer
University of MalayaP2/3CCC (48)
ts-1
Cancer
National University Hospital, SingaporeP2CCC (48)
Tumor Lysate, Particle Only Vaccine
Cancer
Elios Therapeutics, LLCP2CCC (48)
Tuvonralimab
Cancer
Second Affiliated Hospital of Nanchang UniversityP2CCC (48)
vbc101
Cancer
VelaVigo Bio IncP1/2CCC (48)
vbc103
Cancer
VelaVigo Bio IncP1/2CCC (48)
Vedolizumab
Cancer
M.D. Anderson Cancer CenterP1/2CCC (48)
wj05129
Cancer
Suzhou Junjing BioSciences Co., Ltd.P1/2CCC (48)
Ziftomenib
Cancer
Kura Oncology, Inc.P1/2CCC (48)
Zn-A-1041
Cancer
Suzhou Zanrong Pharma LimitedP1/2CCC (48)
Showing 251 to 300 of 1,380 assets
PreviousPage 6 of 28Next